Outcomes of X-Linked Agammaglobulinaemia Patients

Ben Shillitoe,Jaime S. Rosa Duque,Sophie H. Y. Lai,Tsun Ming Lau,Jeffery C. H. Chan,Helen Bourne,Catherine Stroud,Terry Flood,Matthew Buckland,Winnie Ip,Austen Worth,Scott Hackett,Archana Herwadkar,Tanya Coulter,Catherine Blaney,Stephen Jolles,Tomaz Garcez,Eduardo Moya,Saul Faust,Mark S. Pearce,Yu Lung Lau,Andrew R. Gennery
DOI: https://doi.org/10.1007/s10875-024-01829-z
IF: 8.542
2024-11-20
Journal of Clinical Immunology
Abstract:X-linked agammaglobulinaemia (XLA), caused by mutations in BTK , is characterised by low or absent peripheral CD19 + B lymphocytes and agammaglobulinaemia. The mainstay of treatment consists of immunoglobulin replacement therapy (IgRT). As this cannot fully compensate for the immune defects in XLA, patients may therefore continue to be at risk of complications.
immunology
What problem does this paper attempt to address?